Press

Press

2022-05-11 08:00 Acarix AB (publ) publishes Interim Report, January – March 2022 Regulatory
Press release Malmö, Sweden, May 11, 2022 Acarix AB (publ) publishes Interim Report, January – March 2022 Increased commercial momentum and great...
2022-05-06 11:30 Acarix presenterar på Naventus Health Care Summit 2022
Pressmeddelande Malmö, 6 maj 2022 Acarix presenterar på Naventus Health Care Summit 2022 Helen Ljungdahl Round, VD och koncernchef för Acarix...
2022-05-06 11:30 Acarix presents at Naventus Health Care Summit 2022
Press release Malmö, Sweden, May 6, 2022 Acarix presents at Naventus Health Care Summit 2022 Helen Ljungdahl Round, President and CEO of Acarix...
2022-04-20 14:00 Acarix publishes the annual report for 2021 Regulatory
Press release Malmö, Sweden, April 20, 2022 Acarix publishes the annual report for 2021 Today, Wednesday April 20, Acarix is publishing its Annual...
2022-04-20 14:00 Acarix publicerar årsredovisningen för 2021 Regulatory
Pressmeddelande Malmö, 20 april 2022 Acarix publicerar årsredovisningen för 2021 Idag, onsdagen den 20 april, publicerar Acarix sin årsredovisning...
2022-04-11 12:00 Kallelse till årsstämma i Acarix AB Regulatory
Kallelse till årsstämma i Acarix AB Aktieägarna i Acarix AB, org.nr 559009-0667, ("Bolaget") kallas härmed till årsstämma onsdagen den 11 maj 2022...
2022-04-11 12:00 Notice of Annual General Meeting in Acarix AB Regulatory
Notice of Annual General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the annual general...
2022-04-01 08:33 FDA requests supplementary information for Acarix breakthrough designation request for heart failure diagnosis Regulatory MAR
Press release (MAR) Malmö, Sweden, April 1, 2022 FDA requests supplementary information for Acarix breakthrough designation request for heart failure...
2022-04-01 08:33 FDA begär kompletterande information för Acarix ansökan om Breakthrough Designation-status för diagnos av hjärtsvikt Regulatory MAR
Pressmeddelande (MAR) Malmö, Sverige, 1 april 2022 FDA begär kompletterande information för Acarix ansökan om Breakthrough Designation-status...
2022-03-11 12:25 Acarix receives strategic order for the CADScor®System in US Regulatory MAR
Press release (MAR) Malmö, Sweden, March 11, 2022 Acarix receives strategic order for the CADScor®System in US Acarix today announces first order...
2022-03-11 12:25 Acarix erhåller strategisk order av CADScor®System i USA Regulatory MAR
Pressmeddelande (MAR) Malmö, 11 mars 2022 Acarix erhåller strategisk order av CADScor®System i USA Acarix meddelar idag att man vunnit en första...
2022-03-10 09:00 Acarix presents at the Redeye Artificial Intelligence Seminar 2022
Press release Malmö, Sweden, March 10, 2022 Acarix presents at the Redeye Artificial Intelligence Seminar 2022 On March 16 at 1.50pm, Helen Ljungdahl...
2022-03-10 09:00 Acarix presenterar vid Redeye seminarium om artificiell intelligens 2022
Pressmeddelande Malmö, 10 mars 2022 Acarix presenterar vid Redeye seminarium om artificiell intelligens 2022. Den 16 mars kl. 13.50 presenterar...
2022-02-18 09:45 Acarix kapitalmarknadsdag: Uppdatering kring strategi, marknader och målsättningar
2022-02-17 09:54 Rättelse av Pressmeddelande: Acarix AB (publ) publicerar Bokslutskommuniké 2021 Regulatory
2022-02-17 09:54 Correction of press release: Acarix AB (publ) publishes Year-End Report 2021 Regulatory
2022-02-17 08:00 Acarix AB (publ) publicerar Bokslutskommuniké 2021 Regulatory
2022-02-17 08:00 Acarix AB (publ) publishes Year-End Report 2021 Regulatory
2022-02-09 14:15 Acarix lämnar in ansökan om status som Breakthrough Therapy till FDA vid diagnosen hjärtsvikt
2022-02-09 14:15 Acarix submits breakthrough designation request with FDA for heart failure diagnosis
2022-02-09 11:55 Acarix AB (publ) brings forward publication of interim report for fourth quarter to February 17, 2022 Regulatory
2022-02-09 11:55 Acarix AB (publ) tidigarelägger publicering av delårsrapport för fjärde kvartalet till den 17 februari 2022 Regulatory
2022-02-07 14:55 Acarix invites to virtual Capital Market Day
2022-02-07 14:55 Acarix bjuder in till virtuell kapitalmarknadsdag
2022-01-10 13:42 Acarix appoints US based Helen Ljungdahl Round as new CEO Regulatory MAR
2022-01-10 13:42 Acarix utser USA-baserade Helen Ljungdahl Round till ny VD Regulatory MAR
2021-12-29 12:00 Acarix carries out a directed issue of shares to guarantors in conjunction with completed rights issue Regulatory
2021-12-29 12:00 Acarix genomför riktad nyemission av aktier till garanter i samband med avslutad företrädesemission Regulatory
2021-12-20 08:00 Acarix announce final outcome in rights issue Regulatory
2021-12-20 08:00 Acarix offentliggör slutgiltigt utfall i företrädesemission Regulatory
PreviousNext

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.

The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing stable chest pain with suspected CAD and is designed to help reduce millions of unnecessary and costly diagnostic procedures.2 CADScor®System calculates a patient-specific CAD-score non-invasively in 10 minutes with at least 96% confidence (Negative Predictive Value).¹

Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

Learn more
  1. User manual US-FDA v.12.Y, prevalence 10,7%
  2. Shaw LJ, Marwick TH, Zoghbi WA, Hundley WG, Kramer CM, Achenbach S, Dilsizian V, Kern MJ, Chandrashekhar Y, Narula J. Why all the focus on cardiac imaging? JACC Cardiovasc Imaging. 2010 Jul;3(7):789-94. doi: 10.1016/j.jcmg.2010.05.004. PMID: 20633864.